In Helsinn Healthcare S.A., v. Teva Pharmaceuticals USA, Inc., the Federal Circuit interpreted, for the first time, what constitutes an "on-sale" bar under 35 U.S.C. 102(a)(1) of the Leahy-Smith America Invents Act.